Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer's disease Clear and near-term value inflection points, with blinded 6-month ...
We changed the address of the Stockhouse website from www.stockhouse.com to stockhouse.com. When this page refreshes you will be logged in with the new address ...
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month ...
Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026 ...
Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026 CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE ...
ProMIS Neurosciences Inc. (NASDAQ:PMN) announced that its shareholders approved a share consolidation proposal at a special meeting held Monday. According to a statement based on a recent SEC filing, ...
A maximum severity vulnerability, dubbed 'React2Shell', in the React Server Components (RSC) 'Flight' protocol allows remote code execution without authentication in React and Next.js applications.
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) ...
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results